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A B S T R A C T
The matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases that are secreted as inac-
tive precursors, which are activated by cleavage of an N-terminal pro-peptide. Their basic mechanisms of action include
cancer cell growth, differentiation, apoptosis, migration and invasion, and the regulation of tumour angiogenesis and
immune surveillance. The expression of MMP2 and MMP9 has been associated with high potential of metastasis in sev-
eral human carcinomas including breast cancer. The 29 female patients, 9 premenopausal and 20 postmenopausal, aged
from 37 to 79 years were included in this study. Tissue samples were examined in 29 primary and 48 recurrent carcino-
mas using the tissue microarrays which included 102 cores of primary breast carcinomas and 96 of recurrent breast car-
cinomas. Immunohistochemistry determined a pattern of expression for MMP9. The staining was diffuse cytoplasmic,
strong, moderate, faint/weak and negative. The majority of the breast carcinomas stained homogenously for MMP9 on
tumor cells. Statistically significant correlation was found for the expression of MMP9 between primary and recurrent
breast carcinomas in general (p<0.001) and in tumors that were grouped as recurrence before (p=0.039) and after 24
months (p<0.001). Strong expression of MMP9 was observed in primary tumors that recurred after 24 months, median:
162.5 (score range 0–300) and those tumors that recurred before 24 months of the initial diagnosis, median: 102.5 (score
range 0–250) (p=0.026).
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Introduction
The matrix metalloproteinases (MMPs) comprise a
family of zinc-dependent endopeptidases that consist of
more than 21 human MMPs and numerous homologues
from other species. MMPs are multidomain proteins and
are secreted as inactive precursors, which are activated
by cleavage of an N-terminal pro-peptide. Their basic
mechanism of action is degradation of proteins, regula-
tion of various cell behaviours with relevance for cancer
biology. These include cancer cell growth, differentiation,
apoptosis, migration and invasion, and the regulation of
tumour angiogenesis and immune surveillance1. Among
these, gelatinases comprised of gelatinase A (MMP-2)
and gelatinase B (MMP-9), are associated with the malig-
nant phenotype of tumor cells, because of their unique
ability to degrade the type-IV collagen, a major compo-
nent of the basement membrane. The gelatinases are se-
creted as zymogens and cleave to the active form and
their function is tightly regulated by several different
mechanisms2. Many investigators have reported the clin-
ical significance of MMP2 andMMP9 in breast cancer3,4.
The objective of the current project is to investigate
the expression patterns of the MMP9 staining in primary
breast carcinomas and developed local recurrence of the




The study included women with breast cancers which
developed local recurrence of the disease. Breast cancer
tissue, primary mass and tissue from the local recurrence
were obtained from the archival tissue samples at the
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The 29 female patients, 9 premenopausal and 20
postmenopausal, aged from 37 to 79 years were included
in this study. Criteria for inclusion were: histopatho-
logical diagnosis, availability of paraffin-embedded tissue
specimens and clinical data confirming local recurrence
of cancer disease. All patients included were diagnosed
from 1995 to 2007. Tissue samples were examined by two
independent pathologists (D.F.^. and E.M.) to confirm
the presence of malignant tissue, in both material, 29
primary and 48 recurrent carcinomas and to validate
histopathologically primary carcinomas using the classi-
fication of breast tumors according to the WHO5. The tis-
sue microarrays were constructed and they contained
replicate 1-mm cores of tumor tissue, 102 cores of pri-
mary breast carcinomas and 96 of recurrent breast carci-
nomas.
Immunohistochemistry
For immunohistochemistry, tissue microarray slides
were deparaffinised and rehydrated in graded alcohols.
Epitope retrival was carried out depending on the anti-
body we used. The slides were then incubated with pri-
mary antibody provided with the Kit, in a DAKO Tech-
Mate Horizon automated immunostainer (LJL Biosys-
tems Inc, Sunnyvale, USA), 3,3 diamino-bensidin was
used as the chromogen. Substitution of the primary anti-
body with an isotype matched IgG and omission of the
primary antibody served as negative control.
MMP9
The samples were stained by primary antibody for
MMP9, which was a mouse monoclonal antibody toward
a human proform of MMP9 (clone 15W2; NCL-MMP9-
439; Novocastra, Newcastle, UK). Producer’s recommen-
ded dilutions 1:10–1:80 and 60 minutes primary anti-
body incubation at 25 °C resulted in strong cytoplasmic
coloration of cells with invisible nucleus, accompanied
with dark brown background, therefore the procedure
was modified: working dilution was of 1:400 with over-
night pretreatment. As positive control we used strongly
staining normal liver tissue sections. MMP9 antibody is
raised against a 134 amino acid portion of the C-terminal
region of the mature human MMP9 molecule.
ER (estrogen receptors) and PR (progesterone
receptors)
The samples were stained by anti receptor antibody;
monoclonal mouse antibody, anti human estrogen recep-
tor (clone 1D5, isotype IgG1-kappa, DakoCytomation,
Glostrup, Denmark) (dilution 1:50) and monoclonal mou-
se antibody, anti human progesterone receptor (clone
PgR 636, isotype IgG1-kappa, DakoCytomation, Glos-
trup, Denmark) (dilution 1:50). Previously identified
strongly staining tumor tissue sections served as positive
controls.
Ki67 proliferation index
Staining was obtained by monoclonal mouse antibody,
anti Ki67 (MIB-1, 1:75; DakoCytomation, Glostrup, Den-
mark). Positive staining of chromatin in dividing cells
served as internal positive control.
HER2 receptors
HER2 immunostaning was performed using Hercep-
Test (DakoCytomation, Glostrup, Denmark).
Immunohistochemical scoring
ER and PR were evaluated by the Allred score me-
thod6,7. For HER2 staining was used a scoring system ac-
cording to SCO/CAP 2007 guidelines8. Expression of
MMP9 was cytoplasmic on tumor cells. The staining re-
sults were quantified by calculation of a complete H-sco-
re that considers both staining intensity and the percent-
age of cells stained at a specific range of intensities. A
complete H-score was calculated by summing the prod-
ucts of the percentage cells stained at a given staining in-
tensity (0–100) and the staining intensity (0–3). For ex-
ample: a specimen with 10% of cells staining 3+, 30% of
cells staining 2+, 20% of cells staining 1+, and 40% of
cells unstained would have a complete H-score of (3´10)
+ (2´30) + (1´20) = 1109.
Statistical analysis
Various methods of descriptive and analytic biomedi-
cal statistics were used: Spearman correlation test, Chi-
square test, Mann-Whitney U-test. Mann-Whitney U-test
was used for comparison of relative MMP9 expression
between the two different groups. Spearman correlation
test was applied to evaluate the statistical significance
between the two values.
Statistical differences with p value < 0.05 were con-
sidered significant. The data were analyzed by SPSS
PACKAGE Release 7.0 for PC (SPSS Inc, Chicago, USA).
Results
Immunohistochemistry determined a pattern of ex-
pression for MMP9. The staining was stromal and dif-
fuse cytoplasmic, strong, moderate, faint/weak and nega-
tive (Figure 1). The majority of the breast carcinomas
stained homogenously for MMP9 on tumor cells. Expres-
sion of MMP9 was found in 96 out of 102 cores of primary
breast carcinomas (94.1 %) and in 81 out of 96 cores of re-
current breast carcinomas (84.4 %) without any signifi-
cant correlation to clinical stage. Statistically significant
correlation was found for the expression of MMP9 be-
tween primary and recurrent breast carcinomas in gene-
ral (p<0.001) (Figure 2) and in tumors that were grou-
ped as recurrence before (p=0.039) and after 24 months
(p<0.001) (Table 1). Strong expression of MMP9 was ob-
served in primary tumors that recurred after 24 months,
median: 162.5 (score range 0–300) and those tumors that
recurred before 24 months of the initial diagnosis, me-
dian: 102.5 (score range 0–250) (p=0.026) (Figure 3).
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Higher expression of MMP9 was found in recurrent tu-
mors, after 24 months, median: 200.0 (score range 0–
300) and those tumors that recurred before 24 months of
the initial diagnosis, median: 110.0 (score range 0–250)
(p=0.003) (Figure 4). Among data that were not shown
inverse correlation was found for ER (p=0.005) with pri-
mary carcinomas which developed recurrence after 24
months and secondary tumor mass. Statistically significant
correlation was not found for PR (p=0.880), HER2 recep-
tors (p=0.129) and Ki67 proliferation marker (p=0.349).
Discussion and Conclusion
The expression of MMP2 and MMP9 has been associ-
ated with high potential of metastasis in several human
carcinomas including breast cancer10. Controversial data
exists concerning the prognostic value of MMP9 in breast
carcinoma11. In this study high expression of MMP9 in
primary breast carcinoma cells was associated with the
local relapse of the disease, mostly after 24 months after
the initial diagnosis. Scorilas et al. reported that reduced
MMP-9 expression in breast carcinoma cells was associ-
ated with poor prognostic factors such as large tumor
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Fig. 1. Pattern and intensity of MMP9 immunostaining. a) strong cytoplasmic; b) moderate cytoplasmic and stromal; c) negative.
Fig. 2. Correlation between relative expression of MMP9 in
primary and recurrent breast carcinomas.
TABLE 1
CORRELATION BETWEEN RELATIVE EXPRESSION OF MMP9 IN PRIMARY AND RECURRENT BREAST CARCINOMAS
(Spearman correlation)
Recurrence (all) Recurrence ( 24 months) Recurrence (>24 months)
MMP9 rs=0.425, p<0.001 rs= 0.282, p=0.039 rs=0.565, p<0.001
Fig. 3. Comparison between expression of MMP9 in primary car-
cinomas which developed local recurrency before 24 months and
after 24 months (Mann-Whitney U-test): p=0.026.
Fig. 4. Comparison between expression of MMP9 in recurrent
carcinomas which developed tumor mass before 24 months and
after 24 months (Mann-Whitney U-test): p=0.003.
size and poor survival for N-patients12. In our study a
third of the primary carcinomas were smaller than 2 cm,
a second third bigger than 2 cm and the remaining third
were T4 carcinomas (infiltrated and exulcerated skin of
the breast). In the present study, positive MMP9 expres-
sion was related to negative ER in the recurrent carcino-
mas which developed within 24 months after the diagno-
sis of the breast carcinoma was established. A possible
explanation is that positive MMP9 expression may repre-
sent an increase in the active enzyme form that could
lead to metastatic process and increased malignancy, for
example, via enhanced angiogenic activity13. MMP9 ex-
pression, in addition, may be affected by hormones stim-
ulating cell growth and invasiveness via acceleration of
the expression of MMPs including MMP914. McGowan et
al found that MMP-1, -9, -12, -14 and -15, were signifi-
cantly associated with poor outcome. All these MMPs,
apart from MMP9, were also associated with outcome in
the systemically untreated patients, suggesting that the-
se are pure prognostic factors for breast cancer15.
In conclusion, our analysis of a published database
showed that the overexpression of MMP9 on tumor cells
of the primary and recurrent breast carcinomas are pre-
dictors of poor outcome for the breast cancer patients
and finally evaluation of the MMP9 expression may add
information of the behaviour of the cancer with probably
local metastatic potential.
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EKSPRESIJA MATRIKSNE METALOPROTEINAZE 9 U PRIMARNIM I RECIDIVIRAJU]IM
KARCINOMIMA DOJKE
S A @ E T A K
Matriksne metaloproteinaze (MMP) su obitelj endopeptidaza ovisnih o cinku, koje se izlu~uju u obliku inaktivnih
prekursora, a oni se aktiviraju cijepanjem N-terminalnog propeptida. Matriksne metaloproteinaze su uklju~ene u rast
tumorskih stanica, diferencijaciju, apoptozu, migraciju i invaziju, kao i regulaciju tumorske angiogeneze i imuni nadzor.
Ekspresija MMP2 i MMP9 vezana je uz izra`eni metastatski potencijal nekolicine karcinoma u ljudi, uklju~uju}i i kar-
cinom dojke. Dvadeset i devet bolesnica, od kojih 9 u premenopauzi i 20 u postmenopauzi, starosti od 37 do 79 godina,
bile su uklju~ene u ovo istra`ivanje. Ispitani su tkivni uzorci 29 primarnih i 48 recidiviraju}ih karcinoma koriste}i
tkivne mikroareje, a to je uklju~ilo 102 uzorka primarnih i 96 recidiviraju}ih karcinoma dojke. Na~in ekspresije MMP9
u tumorskim stanicama odre|en je imunohistokemijski. Bojenje je bilo difuzno citoplazmatsko, a ja~ina ekspresije oz-
na~ena kao jaka, umjerena i slaba ili negativna. Ve}ina karcinoma dojke eksprimirala je homogeni na~in obojenja cito-
plazme tumorskih stanica na MMP9. Statisti~ki zna~ajna korelacija za ekspresiju MMP9 na|ena je izme|u primarnih i
rekurentnih karcinoma dojke op}enito (p<0.001) i u tumorima grupiranim kao recidivni tumori prije (p=0.039) i na-
kon 24 mjeseca (p<0.001). Jaka ekspresija MMP9 na|ena je u primarnim tumorima koji su recidivirali nakon 24 mje-
seca, median: 162.5 (raspon 0–300) i u onim tumorima koji su recidivirali prije 24 mjeseca od prve postavljene dijag-
noze, median: 102.5 (raspon 0–250) (p=0.026).
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